surmount-1 tirzepatide non-diabetic obesity weight loss Trial SURMOUNT-1: Tirzepatide Drastically Reduces Weight

The molecules bind to some receptors, but not enough to trigger the cascade of effects that produce appetite suppression, improved insulin sensitivity, and the metabolic changes that drive weight loss

6 The aims of this post hoc analysis of SURMOUNT1 were to assess the baseline characteristics and weight reduction achieved at Weeks 24 and 72 by treatment response status at Week 12

At the starting dose of 2.5 mg, you draw 25 units, which is a comfortable volume to measure accurately on most insulin syringes

Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools

everyone responds to medication differently, so remember to discuss and follow personalized recommendations from your healthcare provider

The markings are clear, the increments are fine, and there is little room for error